TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05789082: A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated A

Sponsor: Hoffmann-La Roche · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 320 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$6,204,660

Rescue Site Savings

+$4,084,080

Unlock Full NCT05789082 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05789082 Rescue Dossier →